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Abstract: Essential thrombocythemia (ET) is a neoplastic proliferation of mature myeloid 
cells – in particular, megakaryocytes – leading to persistently elevated platelet count. Usual 
clinical presentation is related to an increase in the risk of hemorrhage and/or thrombosis. Man-
agement of ET consists of antiplatelet therapies – mainly aspirin and cytoreductive therapies. 
Coronary involvement in patients with ET is rare. The optimal treatment strategies for ET 
patients presenting with acute myocardial infarction remains unclear. Acute interventions like 
intracoronary thrombolytic therapy, angioplasty, and coronary-artery bypass grafting have been 
reported in such patients. However, several questions remain unanswered about the acute and 
long-term management of these patients. Herein, we report the case of a 47-year-old female 
who presented with acute myocardial infarction as the first clinical sign of ET, and also present 
the long-term follow-up of this patient.
Keywords: STEMI, platelets, hypercoagulability, thrombosis, antiplatelets
Introduction
Essential thrombocythemia (ET) is a neoplastic proliferation of mature myeloid 
cells – in particular, megakaryocytes – leading to persistently elevated platelet count. It 
is an uncommon disease with an incidence of 2.5 per 1 million.1 Clinical symptoms are 
related to an increase in the risk of hemorrhage and/or thrombosis. Recent studies have 
demonstrated that thrombotic complications in the cerebral, coronary, and peripheral 
vessels are more common than hemorrhagic complication.1,2
ET is a disease that predominantly affects males and females of a median age 
of 60.3 Coronary involvement in patients with ET is rare; however, herein, we report 
the case of a 47-year-old female who presented with acute myocardial infarction (MI) 
as the first clinical sign of ET. We also report the long-term (3-year) follow-up of this 
same patient.
Case presentation
A 47-year-old female patient presented to our emergency department with chest pain. 
The pain was: retrosternal; of sudden onset, starting 2 hours prior to presentation at 
our hospital; continuous and worsening in severity; described as pressure; irradiating 
to the neck and left upper extremity; had no precipitating or alleviating factors; and 
was associated with nausea, diaphoresis, and shortness of breath. She denied headache, 
dizziness, syncope, palpitations, or vomiting. Prior to the pain beginning, the patient 
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denied having any of the symptoms. Review of her system 
was negative except for the symptoms mentioned.
The patient had no significant medical history except 
that she was seen many years prior for mild thrombocytosis 
during her pregnancy. At that time, she was started on aspirin. 
She did not keep her follow-up appointments afterward. Her 
surgical history was significant for hysterectomy.
Her father had had coronary artery disease and MI at the 
age of 50; he died at the age of 67. Her mother had been diag-
nosed with chronic myelogenous leukemia and succumbed 
to blastic crisis after 7 years. Three of the patient’s four 
children were positive for Factor V Leiden and one daughter 
developed extensive deep-vein thrombosis after 4 weeks on 
the oral contraceptive pills and major bleeding on warfarin 
(severe hemorrhagic ovarian cysts).
The patient was a nonsmoker and denied any alcohol or 
drug use. She had no history of allergy. Her only medication 
was baby aspirin once daily.
On initial examination, the patient was awake, alert, and 
oriented. Her blood pressure was 90/60 µg, and she had a 
pulse of 80 beats per minute, respiratory rate of 12 breaths 
per minute, and a temperature of 99°F. There was no jugular 
vein distention. Auscultation was clear throughout both lungs. 
Cardiac auscultation revealed an S4 gallop. No loud mur-
murs were appreciated. Abdominal exam was unremarkable, 
with no hepatosplenomegaly. There was no edema of the 
lower extremities. There was positive erythromelalgia of 
the hands.
Her electrocardiogram showed sinus rhythm and ST- 
segment elevation in the anterior leads from V1 to V6 
 consistent with a large anterior wall infarct (Figure 1).
Initial blood work showed negative cardiac enzymes. 
Her hemoglobin was 13.7 g/dL, white blood cell count was 
14.2 th/mm3, and platelet count was 935,000 th/mm3. The 
patient’s basic metabolic profile was normal. Her low-density 
lipoprotein and high-density lipoprotein were 148 mg/dL and 
61 mg/dL, respectively.
The patient was transferred urgently to the catheterization 
lab. Left heart catheterization showed a total proximal left 
anterior descending artery (LAD) occlusion (Figure 2A), 
while her other coronary arteries were normal. A success-
ful balloon angioplasty, with two bare metal stents, was 
performed on the 100% lesion in the proximal LAD, and an 
excellent result was attained (Figure 2B). The patient was 
started, in addition to aspirin (325 mg daily), on clopidogrel, 
a statin, and beta-blockers. Transthoracic echocardiography 
revealed a left ventricular ejection fraction of 35% with 
severe hypokinesia of the mid-apical anteroseptal and api-
cal walls.
During her hospital stay, the patient was seen by the 
hematology-oncology team. Further workup was done and 
this showed a positive JAK-2 mutation. She was negative 
for the Factor V Leiden mutation (R506Q) and BCR-ABL 
genes translocation (Philadelphia chromosome). The rest 
of her blood work was within normal limits, including 
the erythrocyte sedimentation rate (1 mm/h), ferritin 
Figure 1 electrocardiogram showing more than 2 mm of st elevation from V1 to V6.
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(151 ng/mL), thyroid-stimulating hormone (1.3 mIU/mL), 
folate (10.2 ng/mL), vitamin B12 (382 pg/mL) and bleeding 
time (1.1 min). Patient was diagnosed with ET and started on 
hydroxyurea 1,000 mg twice daily. Patient was discharged 
in a stable condition with the plan to follow up with the 
 cardiologist and hematologist.
Two weeks later, during a follow-up at the hematology 
office, her complete blood count revealed a platelet count 
of 803 th/mm3, so the dose of hydroxyurea was increased to 
2,500 mg twice daily. Subsequent follow-up a few weeks later 
indicated a platelet count of 310 th/mm3, so the patient was 
kept on the same dose for the next 3 years. Her platelet count 
four months ago was still within the normal range.
The patient has been followed-up in the outpatient 
cardiology office for the last 3 years. Within a few months, 
her left ventricular function was found to have improved to 
normal and has been normal since then. We managed her as 
a coronary artery disease (CAD) equivalent, continued on 
dual antiplatelet therapy (aspirin and clopidogrel) beyond 
1 year.
Discussion
ET is a myeloproliferative disorder characterized by abnor-
mal proliferation of megakaryocytes, and it causes thrombus 
formation in the systemic arteries including the coronary 
arteries. Coronary artery involvement leading to acute MI 
is rare compared with other myeloproliferative diseases like 
polycythemia vera (PV).4 Rossi et al followed 170 patients 
with ET for 10 years.4 Only 9.4% of these patients had an MI 
during the follow-up period, and, of those, 75% had additional 
cardiovascular risk factors. There are many theories about the 
factors contributing to MI in ET patients. However, the under-
lying pathophysiological mechanisms still remain unclear. It 
has been reported that hypertension and cigarette smoking 
are risk factors for thrombosis development in patients with 
ET.5 Except for the family history of coronary artery disease, 
our patient, a nonsmoker, had no other traditional risk factors 
for MI, such as dyslipidemia, diabetes mellitus, or hyperten-
sion. According to her profile (age ,60 years, no history of 
thrombosis, and platelet count ,1 million/µL), the patient is 
stratified as low risk for thrombosis and hemorrhage. When 
MI occurs in a patient who does not have these traditional 
risk factors, then alternative etiologies should be investigated. 
They include hypercoagulable states, coronary vasospasm, 
coronary inflammation, anomalous coronary arteries, coronary 
dissection, and embolization.6 Previous investigations for the 
pathogenesis of acute coronary syndrome (ACS) have shown 
the importance of platelet thrombus formation caused by 
vascular endothelial damage resulting from plaque rupture.7 
However, thrombus formation due to abnormal platelet count 
might be the main underlying cause of ACS associated with 
ET. Douste-Blazy et al reported that, in cases of ET, the five 
pathophysiologic mechanisms of thrombus formation in dif-
ferent coronary arteries were: 1) activation of thrombocytes 
as a result of endothelial damage, 2) extended arterial spasms 
resulting in formation of thrombus, 3) increased procoagulant 
activity of thrombocytes, 4) changes in glycoproteins on the 
surface of thrombocytes, and 5) possible deficiency of selec-
tive lipoxygenase.8
Hypercoagulable states are associated with myelo-
proliferative disorders such as PV, chronic myelogenous 
leukemia, ET, and primary myelofibrosis. Patients with 
myeloproliferative disorders have an elevated risk of both 
hemorrhage and thrombosis. Thrombotic complications are 
more prevalent than hemorrhagic complications.9 Throm-
botic occlusions occur more frequently in the arteries than 
veins; further, strokes are the most frequent presentation, 
followed by MI and peripheral arterial occlusion.6
In ET, megakaryocytes exhibit an increased sensitivity 
to thrombopoietin.10 An important question to ask at this 
point is what are the central molecular mechanisms that 
underlie the activation of the coagulation system and lead 
to thrombosis? Janus kinase (JAK) is an intracellular protein 
kinase.  Phosphorylation of JAK activates cytoplasmic signal 
transducers and activators of transcription (STAT).11 The 
STAT proteins then shuttle into the nucleus and activate the 
downstream pathways in thrombopoietin and erythropoi-
etin signaling, as well as activating receptors for cytokines, 
colony stimulating factors, and interferons.6,11 The JAK2 
V615 mutation, an acquired somatic mutation, results in a 
mutated tyrosine kinase that continuously activates the STAT 
proteins, which, in turn, activate the downstream pathways 
Figure 2 Left coronary angiography (right anterior oblique cranial). (A) proximal 
total occlusion of the left anterior descending artery. (B) successful angioplasty with 
two bare metal stents.
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discussed. The presence of a JAK2 mutation has become a 
major diagnostic criterion for PV, ET, and myelofibrosis.6
Management of ET consists of antiplatelet therapies – 
mainly aspirin and cytoreductive therapies that consist of phle-
botomy, hydroxyurea, anagrelide, interferon-α, and ruxolitinib, 
which is an inhibitor of JAK1 and JAK2 (and recently approved 
by the US Food and Drug Administration).6 Aspirin combined 
with cytoreductive therapy is thought to be highly effective 
in PV and ET patients.3 Antiplatelet therapy should be used 
with caution and its benefits weighed against the risks of seri-
ous bleeding, especially in patients with a platelet count of 
1,000 × 10/L.10,12 Cytoreductive therapies are considered in 
patients with myeloproliferative disorders who are over the 
age of 60, at high risk for thrombotic events, have a significant 
history of thrombotic or hemorrhagic events, and a platelet 
count .1.5 million/mm3.3 Cytoreductive therapies must also 
be weighed against the risk of leukemic transformation.
The optimal treatment strategies for ET patients pre-
senting with acute MI remain unclear. Acute interventions 
like intracoronary thrombolytic therapy, angioplasty, and 
coronary-artery bypass grafting have been reported in such 
patients.13 Intracoronary thrombus remains a challenge for 
interventional catheter-based techniques, and distal embo-
lization is considered to be a major cause of insufficient 
reperfusion.14 A previous report showed that the use of both 
aspiration thrombectomy and distal protection to prevent 
distal embolization achieved a successful angioplasty without 
complications.15 Mizuta et al reported a case of acute MI in 
a patient with ET treated with percutaneous transluminal 
coronary recanalization by administration of urokinase that 
resulted in successful revascularization with thrombolysis in 
myocardial infarction (TIMI) grade III coronary flow.5
However, there is no clear evidence on how to manage 
these patients on a long-term basis and whether we should 
treat them as atherosclerotic CAD equivalent. A previous 
study showed that a history of thrombosis at diagnosis was 
significantly associated with recurrent thrombosis.16 Fur-
ther, in a review by Landolfi and Di Gennaro, the authors 
considered that more aggressive antiplatelet therapy with 
a combination of aspirin and clopidogrel in patients with 
ACS, like our patient, might be beneficial for preventing re-
thrombosis.17 In our case, the patient had no risk factors for 
CAD except family history, and we knew that the etiology 
of her MI was thrombotic process; despite that, we managed 
her as per American College of Cardiology/American Heart 
Association guidelines18 for CAD. Our patient has done well 
over the last 3 years, never complaining of any symptoms or 
acute events over that time.
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